Trial Profile

A Multi Center, Open Label, Long Term Study of S5G4T-1 to Evaluate the Safety of S5G4T-1 in Papulopustular Rosacea Patients

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 17 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Benzoyl peroxide (Primary)
Indications Rosacea
Focus Adverse reactions; Registrational
Sponsors Sol-Gel Technologies

Most Recent Events

13 Dec 2021 Status changed from completed to discontinued.
06 Aug 2020 According to an Sol-Gel Technologies media release, the company has submitted the NDA for Epsolay for the treatment of papulopustular rosacea. The company looks forward to the FDA confirming acceptance and granting a PDUFA action date in the near future.
17 Mar 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com